Published in J Immunol on June 01, 1982
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med (1983) 2.67
In vitro binding of natural killer cells to Cryptococcus neoformans targets. Infect Immun (1985) 1.30
Natural killer cells are present in the normal human lung but are functionally impotent. J Clin Invest (1984) 1.11
Natural killer cells and spontaneous cell-mediated cytotoxicity in the human intestine. Clin Exp Immunol (1984) 0.93
Natural killer cells in normal pregnancy: analysis using monoclonal antibodies and single-cell cytotoxicity assays. Clin Exp Immunol (1985) 0.88
Effect of simple sugars on natural killing: evidence against the involvement of a lectin like mechanism in target recognition. Clin Exp Immunol (1983) 0.82
Recruitment of OKM1 staining lymphocytes with selective binding to K-562 tumour targets by interferon. Clin Exp Immunol (1983) 0.78
Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease. Clin Exp Immunol (1985) 0.75
Natural killing and growth inhibition of K562 cells by subpopulations of mononuclear cells as a function of target cell proliferation. Immunology (1984) 0.75
The Chediak-Higashi gene in humans. III. Studies on the mechanisms of NK impairment. Clin Exp Immunol (1983) 0.75
Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci U S A (1993) 20.33
Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys (1995) 3.86
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys (2001) 3.70
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron (1999) 3.50
Distinction awards and racial discrimination. BMJ (1998) 3.33
Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol (1981) 2.92
Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci (1997) 2.89
Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1. J Neurophysiol (2001) 2.76
Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med (1993) 2.53
Target-effector interaction in the natural killer (NK) cell system. II. The isolation of NK cells and studies on the mechanism of killing. J Immunol (1978) 2.29
CAKbeta/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. Neuron (2001) 2.22
The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol (1979) 2.11
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med (1990) 2.03
The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function. Neuron (2001) 2.02
The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect. J Immunol (1979) 2.02
Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys (1993) 1.99
The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: the Radiation Therapy Oncology Group 75-06 and 77-06 experience. Int J Radiat Oncol Biol Phys (1991) 1.88
Accurate recovery of articulator positions from acoustics: new conclusions based on human data. J Acoust Soc Am (1996) 1.83
Src activation in the induction of long-term potentiation in CA1 hippocampal neurons. Science (1998) 1.81
Precision of automatic measurements of pigmented skin lesion parameters with a MelaFind(TM) multispectral digital dermoscope. Melanoma Res (2000) 1.78
A new immunodeficiency disorder in humans involving NK cells. Nature (1980) 1.78
Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1. Nature (1984) 1.77
Regulation of T cell activation, anxiety, and male aggression by RGS2. Proc Natl Acad Sci U S A (2000) 1.73
Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. Proc Natl Acad Sci U S A (1982) 1.73
Spontaneous human lymphocyte-mediated cytotoxicity againts tumour target cells. I. The effect of malignant disease. Int J Cancer (1976) 1.71
Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys (1995) 1.71
Target-effector interaction in the natural killer cell system: isolation of target structures. Proc Natl Acad Sci U S A (1979) 1.71
Target--effector interaction in the natural killer cell system. I. Covariance and genetic control of cytolytic and target-cell-binding subpopulations in the mouse. Scand J Immunol (1978) 1.70
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest (1997) 1.63
The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis (1993) 1.62
Intrauterine growth retardation and premature delivery: the influence of maternal smoking and psychosocial factors. Am J Public Health (1996) 1.59
RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys (1995) 1.57
Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys (1996) 1.57
Antigenic competition: a review of nonspecific antigen-induced suppression. Adv Immunol (1974) 1.55
Early and persistent alterations in the expression of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. Radiat Res (1996) 1.55
Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys (1989) 1.52
Cancer of the gastrointestinal tract. Comment: Early detection. JAMA (1974) 1.50
Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys (1998) 1.49
Atenolol determination by high-performance liquid chromatography and fluorescence detection. J Chromatogr (1979) 1.47
Neurological abnormalities in schizophrenic patients: a prospective follow-up study 5 years after first admission. Acta Psychiatr Scand (1999) 1.47
Progressive atrophy of the frontal lobes in first-episode schizophrenia: interaction with clinical course and neuroleptic treatment. Acta Psychiatr Scand (1999) 1.46
Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique. J Immunol (1981) 1.45
Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. Ophthalmology (1996) 1.44
Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice. Nature (1980) 1.42
A survey of resuscitation training in Canadian undergraduate medical programs. CMAJ (1992) 1.39
Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys (1993) 1.38
Natural killer cells. Prog Allergy (1981) 1.38
Reduced fear and aggression and altered serotonin metabolism in Gtf2ird1-targeted mice. Genes Brain Behav (2007) 1.37
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med (1993) 1.32
Evidence that many of the DISC1 isoforms in C57BL/6J mice are also expressed in 129S6/SvEv mice. Mol Psychiatry (2007) 1.32
High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1. J Immunol Methods (1994) 1.32
Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes. Clin Exp Immunol (1975) 1.31
Microcirculation of tumors. I. Anatomy, function, and necrosis. Clin Radiol (1966) 1.29
Understanding the problem of understaging in ovarian cancer. Semin Oncol (1975) 1.29
Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. Clin Immunol Immunopathol (1998) 1.28
Extradural spinal cord compression by tumor. II. High daily dose experience without laminectomy. Radiology (1969) 1.27
Recombinant myelin-associated glycoprotein confers neural adhesion and neurite outgrowth function. Neuron (1989) 1.25
Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys (2000) 1.23
Chemiluminescence response of human natural killer cells. I. The relationship between target cell binding, chemiluminescence, and cytolysis. J Exp Med (1982) 1.23
Oxygen intermediates are triggered early in the cytolytic pathway of human NK cells. Nature (1982) 1.22
Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis. Int J Radiat Oncol Biol Phys (1994) 1.22
Clinical radiation pathology as applied to curative radiotherapy. Cancer (1968) 1.20
Target-effector interaction in the natural killer cell system. IV. Modulation by cyclic nucleotides. J Immunol (1979) 1.20
Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax (1991) 1.20
High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys (1979) 1.20
An expanded population of natural killer cells in mice with severe combined immunodeficiency (SCID) lack rearrangement and expression of T cell receptor genes. J Exp Med (1986) 1.19
Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys (2001) 1.19
Organization of a repetitive human 1.8 kb KpnI sequence localized in the heterochromatin of chromosome 15. Chromosoma (1985) 1.19
Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein kinase C, and activation of Src. J Neurosci (2005) 1.18
The spread of glioblastoma multiforme as a determining factor in the radiation treated volume. Int J Radiat Oncol Biol Phys (1977) 1.16
The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol (1992) 1.16
The immune response to sheep erythrocytes in the mouse. I. A study of the immunological events utilizing the plaque technique. J Exp Med (1967) 1.15
Dynamics of intergestural timing: a perturbation study of lip-larynx coordination. Exp Brain Res (1998) 1.15
Target-effector cell interaction in the natural killer cell system. V. Energy requirements, membrane integrity, and the possible involvement of lysosomal enzymes. Immunology (1980) 1.15
Ocular and orbital complications following radiation therapy of paranasal sinus malignancies and review of literature. Cancer (1983) 1.14
Origin and partial characterization of Fc receptor-bearing cells found within experimental carcinomas and sarcomas. Int J Cancer (1975) 1.14
A functional comparison of tumor cell killing by activated macrophages and natural killer cells. Eur J Immunol (1979) 1.12
Binding specificities of the sialoadhesin family of I-type lectins. Sialic acid linkage and substructure requirements for binding of myelin-associated glycoprotein, Schwann cell myelin protein, and sialoadhesin. J Biol Chem (1997) 1.12
Inducible cellular transformation by a metallothionein-ras hybrid oncogene leads to natural killer cell susceptibility. Nature (1986) 1.11
The biology of the human natural killer cell. J Clin Immunol (1982) 1.11
An assessment of intratumor phagocytic and surface marker-bearing cells in a series of autochthonous and early passaged chemically induced murine sarcomas. J Natl Cancer Inst (1976) 1.11
Impaired cerebellar synaptic plasticity and motor performance in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. J Neurosci (1996) 1.11
Absolute measurement of hadronic branching fractions of the Ds+ meson. Phys Rev Lett (2008) 1.09
Suppressor cells in immunosenescence. Fed Proc (1978) 1.08
A study of smoking and smoking cessation on the curricula of UK medical schools. Tob Control (2004) 1.07
The standardization of NK cell assays for use in studies of biological response modifiers. J Immunol Methods (1984) 1.06
Intra-rectal injection of tumour cells: a novel animal model of rectal cancer. Surg Oncol (1992) 1.06
Carbogen breathing during radiation therapy-the Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys (1980) 1.06
Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys (1988) 1.06
Patterns of human interlimb coordination emerge from the properties of non-linear, limit cycle oscillatory processes: theory and data. J Mot Behav (1981) 1.05
Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma. Hybridoma (1982) 1.04
New syndrome manifested by mandibular hypoplasia, acroosteolysis, stiff joints and cutaneous atrophy (mandibuloacral dysplasia) in two unrelated boys. Birth Defects Orig Artic Ser (1971) 1.04
Prazosin protein binding in health and disease. Br J Clin Pharmacol (1980) 1.04